Yokogawa Acquires Insilico Biotechnology, Developer of Modern Bioprocess Digital Twin Know-how

Yokogawa broadcasts that it has acquired all shares of Insilico Biotechnology AG (“Insilico”), a Stuttgart, Germany-based developer and supplier of bioprocess software program and providers. Fostering the event of the bioeconomy is among the precedence points inside Yokogawa’s sustainability targets, and according to that the corporate goals to leverage this acquisition to construct complete bioprocess options that help biopharmaceutical growth by means of to manufacturing.

Pushed by developments such because the COVID-19 pandemic, demand continues to develop for biopharmaceuticals which have fewer unwanted effects and can be utilized to deal with sufferers with uncommon and intractable situations. In distinction to the manufacturing of chemically synthesized general-purpose prescribed drugs, the general value of biopharmaceuticals is increased, and the complicated cell cultivation course of required to effectively and stably get hold of the goal proteins calls for rigorous high quality management measures that pose important challenges with mass manufacturing.

The cells cultivated in a bioreactor are immense in quantity. As every of those cells generate the fabric that kind the lively substances in prescribed drugs, it’s essential to observe their particular person metabolic reactions. The actual-time visualization and evaluation of any environmental elements equivalent to adjustments in pH and dissolved oxygen focus are additionally crucial. As such, it has been extraordinarily tough to hold out cell manufacturing by controlling the complicated cell response methods with a lot of set parameters.

Insilico’s digital twin know-how makes use of a sophisticated hybrid mannequin fashioned from a mechanistic mannequin*1 of the distinctive traits of an intracellular metabolic community and a data-driven mannequin*2 constructed from course of knowledge utilizing the machine studying course of. In addition to drastically accelerating what till now has been a multiple-year growth course of, prediction and simulation additionally allow the acquisition of a deep understanding of the metabolism course of. And provided that this answer permits the development of metabolism fashions for micro organism and plenty of other forms of mobile organisms, it can be utilized in all kinds of functions associated to meals, chemical substances, and different merchandise that make the most of biotechnology.

In manufacturing too, Insilico’s digital twin know-how permits the real-time evaluation of course of knowledge, which permits for the fixed prediction of cultivation efficiency, the tender sensing of dietary elements that can’t be measured immediately, and the early detection of course of abnormalities and provision of steering to operators. By deploying this problem-solving know-how, product high quality may be stabilized, which contributes to environment friendly mass manufacturing.

Klaus Mauch, CEO of Insilico Biotechnology AG, says:

There are excessive expectations for this fusion between our cutting-edge digital twin software program know-how for bioprocesses and Yokogawa’s pharmaceutical manufacturing system options. I consider that by means of Yokogawa’s world community we can increase our gross sales channels and make an awesome contribution to the biopharmaceuticals business.”

Hiroshi Nakao, a Yokogawa vice chairman and head of the corporate’s Life Enterprise Headquarters, says:

I firmly consider that the modern digital twin know-how supplied by Insilico, which has a confirmed observe document with main biopharmaceutical firms, will speed up digital transformation within the bioprocessing business. We’ll leverage our engineering know-how and develop our enterprise with a view to the commercialization of bioprocesses.”

Overview of Insilico Biotechnology AG

  • Established: 2001
  • Location: Stuttgart, Germany
  • CEO: Klaus Mauch
  • Variety of staff: 29
  • Enterprise: Improvement of digital twin-based software program and provision of providers for bioprocesses
  • Web site: https://www.insilico-biotechnology.com/

*1 Mechanistic mannequin: A mannequin that’s developed primarily based on the elemental ideas of the related response or mechanism, so a deep data and understanding of the method is required to assemble the mannequin. The mannequin that’s obtained because of this has variables and parameters that may be bodily interpreted, and superior generalization is feasible. Nevertheless, a excessive precision bodily mannequin requires excessive growth and computation prices.

*2 Knowledge pushed mannequin: In distinction to mechanistic fashions, no data of the elemental ideas of the related course of is required. The benefits of this embrace easy implementation and comparatively low growth and computation prices. Nevertheless, disadvantages embrace difficulties in deciphering knowledge after forecasting or simulation is carried out and generalizing outcomes. Requiring giant volumes of course of knowledge to assemble the mannequin is one other downside of this system.


  • https://www.yokogawa.com/information/press-releases/2021/2021-11-02/

#Yokogawa #Acquires #Insilico #Biotechnology #Developer #Modern #Bioprocess #Digital #Twin #Know-how